Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tug Of War In The LVAD Market

Executive Summary

With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.

You may also be interested in...



Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges

Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.

European Markets Show Pockets Of Strong Growth For Cardiovascular Devices

The big five European Union markets – Germany, France, the UK, Spain, and Italy – are expected to see strong growth in some of the more common cardiovascular device implant procedures over the next four years, with ventricular assist device (VAD) implantations topping the list. All five major EU markets are forecast to experience healthy mid-teen compound annual growth rates in VAD implantation volume, according to recently published European procedure volume reports from Medtech Insight.

LVAD Companies Address Thrombosis Fears Raised In NEJM Report

The CEOs of Thoratec and HeartWare addressed the recent highly publicized report on the risk of LVAD thrombosis at the J.P. Morgan Healthcare Conference.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel